

## ANALYSIS OF RIFAMPICIN INDETERMINATE RESULTS USING SHEWHART CONTROL

### CHARTS: IMPLICATIONS FOR PATIENTS AND TUBERCULOSIS CONTROL PROGRAMMES

Taagbara Jolly Abaate<sup>1</sup>, Aloni Adolphus Alali<sup>2</sup>

1. Department of Community Medicine, University of Port Harcourt Teaching Hospital.

2. Department of Community Medicine, River State University. Email: [alonialali@gmail.com](mailto:alonialali@gmail.com)

Tell: +2348033421555

Corresponding author: Taagbara Jolly Abaate, [abaatejt83q@gmail.com](mailto:abaatejt83q@gmail.com)

#### **Abstract**

#### **Background**

Antimicrobial resistance is a growing global public health concern, and multidrug-resistant tuberculosis is responsible for roughly one-quarter of all antimicrobial-resistant infection-related deaths worldwide. GeneXpert is a rapid, automated molecular test that detects multi-drug-resistant tuberculosis using rifampicin as a predictor. It was recommended by the World Health Organization (WHO) in 2010 for national tuberculosis programs in developing countries; however, it has limitations. Indeterminate results for *Mycobacterium tuberculosis* indicate that the test was unable to determine whether the bacteria were resistant to rifampicin. This study used Shewhart Control Chart, which has action limits, to investigate the causes of indeterminate results.

#### **Methods**

The control limits on the Shewhart chart are central, upper, and lower. GeneXpert indeterminate results obtained between January 2017 and December 2020 in a tertiary hospital in a low and middle-income country were plotted. Points above the upper control limit were used to determine whether or not the process was under control.

#### **Result**

The proportion of GeneXpert results that were indeterminate varied, with 58% exceeding the upper limit. Only 42% were within the control limit, in comparison.

The majority of the laboratory results revealed an out-of-control signal by displaying points outside the control limits or non-random patterns of points known as special-cause variation, according to this study.

### **Conclusions**

GeneXpert indeterminate results have an impact on patient management by preventing accurate diagnosis and delaying the start of anti-tuberculosis medication. Machine malfunctions, insufficient bacterial load, poor quality samples, operator errors, or faulty laboratory materials could all be to blame. Regular equipment checks by laboratory personnel, program sponsors, or leadership will be extremely beneficial in achieving the desired results and initiating appropriate treatment. Statistical process control is widely used in hospital performance monitoring and improvement, and it is becoming more popular in public health surveillance.

***Keywords:*** *INDETERMINATE, GENEXPERT, SHEWHART, CONTROL CHARTS*

## BACKGROUND

With an estimated 10.4 million TB cases and 600,000 new drug resistance cases worldwide<sup>1-7</sup>, tuberculosis (TB) kills more people than any other single infection. The global burden of tuberculosis cases and drug resistance is increasing<sup>1, 2</sup>, and many patients continue to rely solely on an ineffective diagnostic test developed more than a century ago<sup>3</sup>.

Tuberculosis is still a major public health concern around the world, with over 90% of TB cases occurring in low and middle-income countries like Nigeria.

<sup>4</sup> In 2018, the 30 most epidemiologically burdened TB countries accounted for 87% of new TB cases, with eight of these countries, including Nigeria, accounting for two-thirds of new TB cases. <sup>6</sup> Nigeria still has the highest TB burden in West Africa. <sup>4, 5</sup> it is also one of 14 countries with a high burden of TB,

TB/HIV, and Multi-Drug Resistant TB. <sup>2, 6</sup> Rapid global increases in tuberculosis (TB) and multidrug-resistant tuberculosis (MDR-TB) have highlighted the importance of rapid diagnostic techniques. Recent molecular diagnostic techniques have been recommended due to their quick turnaround time and high sensitivity and specificity.<sup>8</sup>

A molecular diagnostic technique; GeneXpert MTB/RIF (Cepheid Inc.) is a rapid, automated test for

MTB detection and RIF (rifampicin resistance) <sup>8-10</sup>. The assay is based on nested real-time PCR and molecular beacon technology. In less than two hours, the results are obtained<sup>10</sup>. The World Health

The organization (WHO) recommended the GeneXpert MTB/RIF assay in 2010 and continues to do so for national tuberculosis programs in developing countries.<sup>9</sup> The gene Xpert MTB/RIF assay can detect potential MDR-TB immediately, breaking the barrier of delayed diagnosis in MDR-TB control. <sup>3, 5</sup>

Because RIF resistance usually coexists with INH resistance, it is a predictor of MDR-TB. <sup>9, 10</sup> Rapid RIF resistance diagnosis allows TB patients to begin effective treatment sooner than other types of drug susceptibility testing<sup>6</sup>. Rapid results from the gene Xpert MTB/RIF assay may help patients who do not have tuberculosis save money by avoiding unnecessary treatment and respiratory isolation in hospitals or other institutions<sup>8</sup>. The results of the gene Xpert MTB/RIF assay indicate whether MTB was detected in the sample, and in some cases, the result is

"invalid," indicating that the test should be repeated. If MTB was discovered, the results will show whether resistance to RIF was discovered, not discovered, or was indeterminate<sup>3-9</sup>.

Positive GeneXpert results for MTB with RIF resistance indicate that the bacteria are likely to be RIF resistant, which should ideally be confirmed by additional rapid sensitivity testing<sup>9-12</sup>. However, because the rapid test is not readily available in Nigeria, most Directly Observed Treatment Short Course (DOTS) centers refer patients to MDRTB centers when RIF resistance is detected using GeneXpert molecular testing. <sup>13-17</sup> Positive results for MTB but indeterminate for RIF resistance indicate that the test was unable to accurately determine whether the bacteria were resistant to RIF; therefore, in such cases, growth-based susceptibility testing to first-line TB drugs should be performed, <sup>15-18</sup>.

Although the gene Xpert MTB/RIF test represents a significant advancement in TB diagnostic testing, it does have limitations, including a limited shelf-life for diagnostic cartridges, some operating temperature and humidity restrictions, the need for electricity, unknown long-term robustness, and the requirement for annual servicing and calibration of each machine. <sup>3-14</sup>. Laboratories in low and middle-income countries, such as Nigeria, are littered with expensive equipment that is no longer functional because it was donated to the incorrect setting. Ensuring the long-term availability of servicing and consumables may be more important and difficult than implementing the diagnostic equipment itself. <sup>16, 19</sup>

Rifampicin resistance detection, as well as early diagnosis and improved case detection, are critical to improving individual patients' health and preventing MDR-TB transmission in the community.<sup>16</sup>

Tuberculosis is diagnosed using smear microscopy in 24-28 hours, whereas solid culture takes 4-8 weeks.

Early diagnosis and treatment are hampered by this diagnostic lag.

Similarly, test failures or unsuccessful test results caused by process errors delay or prevent some patients from receiving a diagnosis. During the early stages of geneXpert<sup>15-17</sup> implementation, other countries expressed similar concerns about high rates of error and invalid results.

In the laboratory, temperature-related, technical problems, cartridge malfunction, electrical connection, and machine malfunction errors are all possibilities<sup>18</sup>. Other sources of inaccurate Xpert results have been identified as human errors such as noncompliance with Standard Operating Procedures (SOP) during sample processing, filling reaction

tubes with viscous sputum or incorrect sample volumes, clogged filters due to the presence of debris in sputum, compromised probe integrity, and module failures<sup>18-20, 19-21</sup>

According to one study, 20 high rates of failed test results demonstrated that early diagnosis, which is critical to TB control, may not be possible in many people if gene Xpert is not managed properly.

Patients who receive false positive RIF-resistant GeneXpert results are more likely to be treated with second-line anti-TB drugs, which are known to be toxic to patients and have significant financial implications for the national TB program. MTB concentrations of 5, 6, 16, and 20 are low or very low in

samples with non-conforming RIF susceptibility reports, implying that bacterial load influences the interpretation of RIF resistance and indeterminate strains.<sup>9, 10, 21</sup> Previous research has found that an unfixed bacterial load affects RIF susceptibility status <sup>21</sup>. The assay's ability to distinguish between mutated and wild-type sequences in the *rpoB* gene's core region may be limited due to the low bacterial load.

When MTB concentrations are very low and resistance cannot be determined, RIF indeterminate results have also been observed<sup>19 21</sup>. When running the gene Xpert test, the first and last probes with CT values that exceed the predefined limits may be reported as RIF sensitive<sup>18-22</sup>. As a result, GeneXpert assay parameters should be reviewed, particularly the CT cut-offs for establishing RIF resistance and indeterminate status.<sup>30,32</sup> This is done to lessen the negative effects of misdiagnosis on not only the patient but also on the TB program and the community as a whole. <sup>2</sup> Walter Shewhart variation theory categorizes variation as coming from a "common cause" or a "special cause," and it guides the appropriate action needed to address these variations and provide continuous improvement. <sup>31</sup>.

A common cause variation is expected as a result of chance.<sup>31, 39</sup> it is present in all processes and has an impact on everyone involved. We must change the underlying process to reduce common cause variation. <sup>31</sup> Special cause variation, on the other hand, is an unusual variation that does not occur by chance but rather as a result of specific circumstances and thus does not affect everyone involved in the process. Special cause variation can produce either exceptionally good or exceptionally bad results<sup>31</sup>, and to reduce unfavorable special cause variation, we must first identify it and then act on it. We must also investigate and learn from favorable special cause variations for the benefit of others. <sup>29, 31</sup>

Control charts have been proposed for use in clinical governance and performance monitoring in healthcare.<sup>28, 29</sup>. The inconsistency and indeterminacy of the gene Xpert assay, which is commonly seen in the DOTS clinic at a tertiary healthcare facility in Rivers state Nigeria, were investigated using control charts. The goal of this paper is to describe a method for evaluating variation in GeneXpert proportions and to attempt to quantify inconsistencies in laboratory GeneXpert results.

## THE OBJECTIVE OF THE RESEARCH

The purpose of this research was to determine whether the output of the GeneXpert process in DOTS at a tertiary center in Port Harcourt, Rivers state, Nigeria, was under control, and if so, whether the variations (if any) in Rifampicin indeterminate GeneXpert results from these laboratories were due to special course variations or common course variations.

## METHODS

GeneXpert data routinely collected from hospital laboratories in DOTS clinics were obtained. The data included the number of sputa taken per month and the number of indeterminate results observed in the same month from 2017 to 2020. We investigated the internal consistency of the laboratory GeneXpert results using P-charts. P-charts are a type of control chart that is intended to be used with binomial data (yes or no) expressed as a proportion of the sample size. <sup>33-35</sup> we ordered our data by the total number of results and plotted our P-charts accordingly. One advantage is that the resulting P-charts produce visually appealing control limits because they resemble a funnel. Such plots have been proposed in the medical field.<sup>30</sup> SPSS version 23.0 was used for all analyses.

## RESULTS

The proportion of indeterminate GeneXpert results varied, with 58% exceeding the upper limit. In comparison, only 42% were within the control limit.




Figure 1. Control chart with five successive points on the same side of the centerline

## DISCUSSION

Control chart-based monitoring begins with selecting the type of chart to use. To investigate inconclusive gene Xpert results, the Shewhart control chart, a simple, low-cost, effective tool with high sensitivity and specificity, was used. During the study period, an estimated 58% of total results were outside the upper control limit, while 42% were within it. During the study period, the majority of the laboratory's results showed an out-of-control signal, indicating a faulty process that could have been caused by machine issues, operator errors, sputum quality, or faulty laboratory materials. On a control chart for a controlled process, points are distributed at random. In other words, it only differs from sources common to the process (called common-cause variation). Figure 1 depicts an out-of-control process by displaying points that are outside the control range or non-random patterns of points (referred to as special-cause variation).

Patients who could have benefited from early resistance detection and MDRTB treatment may be delayed as a result of an incorrect indeterminate result. As a result, the disease burden will worsen and the program's costs will rise.

Shewhart control charts were used in a UK study to analyze inadequate cervical smears, and the results guided quality improvement. <sup>31</sup> While similar methodologies for quality control of Xpert results have not been used in

Nigeria or elsewhere, statistical process control has been widely used in hospital performance monitoring and improvement and is increasingly being adopted for public health surveillance. 33-35

#### STRENGTHS AND LIMITATIONS OF THIS STUDY

The ultimate goal of data is to provide a foundation for action to support improvement, and this study sheds light on the clinical quandary of starting anti-tuberculosis treatment. Shewhart control charts have high sensitivity and specificity, and they are the most common and easiest to build. They work by plotting one data point at a time.

Because this was a population-based study, our findings reflect the quality control issues that most reference laboratories face. Control charts are unpopular among researchers, and this is the first study to use a statistical control tool to examine the stability of quality control measures in the laboratory.

Due to the complexities and time constraints of this study, we did not use the CUSUM charts, which have higher sensitivity and specificity (35, 39).

Because this was a total population study, our findings reflect normal laboratory operations. Points could have strayed beyond the upper or lower control limits, resulting in a false alarm or type 1 error.

The presence of five consecutive points with more than one standard deviation and greater than three sigmas on the same side of the centerline was used to identify special cause variation. Other, more sensitive, and specific detection rules have been proposed. 36, 37, and should be investigated further in future research.

#### CONCLUSION

GeneXpert indeterminate results have an impact on patient management by preventing accurate diagnosis and delaying the start of anti-tuberculosis medication. Machine malfunctions, insufficient bacterial load, poor quality samples, operator errors, or faulty laboratory materials could all be to blame. Regular equipment checks by laboratory personnel, program sponsors, or leadership will be extremely beneficial in achieving the desired results and initiating appropriate treatment. Statistical process control is widely used in hospital performance monitoring and improvement, and it is becoming more popular in public health surveillance.

#### ETHICAL APPROVAL.



The Research and Ethics Committee of the University of Port Harcourt Teaching Hospital in Rivers state, Nigeria, granted ethical approval. The authorization ID is UPTH/ADM/90/S.II/VOL.XI/1470.

#### DISSEMINATION:

The findings from this study will be presented at both local and international conferences and published in key peer-reviewed journals.

#### ACKNOWLEDGMENTS.

We sincerely thank the staff of the DOTs clinic for collecting the data and making it available for analysis.

#### CONFLICT INTEREST STATEMENT.

There is no conflict of interest, declares the authors. The lead author (AJT) attests that the manuscript is a truthful, accurate, and transparent account of the study that is being reported; that no significant elements of the study have been omitted; and that any discrepancies from the study as planned have been explained for this study.

#### CONTRIBUTORS.

ATJ designed and conceptualized the study methodology, while AA performed the primary statistical analysis. All authors approved the final version of the manuscript, and they all contributed significantly to its revision and editing. The corresponding author certifies that all listed authors meet the requirements for authorship and that no other authors who meet the requirements were overlooked.

#### FUNDING.

No funding from a funding agency in the public, private, or nonprofit sectors.

#### PROVENANCE AND PEER REVIEW:

Not commissioned; peer-reviewed externally.

## REFERENCES

1. Dirlikov E, Raviglione M, Scano F. Global tuberculosis control: toward the 2015 targets and beyond. *Annals of internal medicine*. 2015 Jul 7; 163(1):52-8.
2. TB in Nigeria - Funding, children, diagnosing TB, HIV/TB [online] accessed Saturday 21/12/2019, available at <https://tbfacts.org/tb-nigeria/>
3. Centers for Disease Control and Prevention. A New Tool to Diagnose Tuberculosis: The Xpert MTB/RIF Assay. Atlanta, GA, USA: CDC. 2013. accessed [online] on Saturday 21/12/2019 available at [https://www.cdc.gov/tb/publications/factsheets/testing/xpert\\_mtb-rif.htm](https://www.cdc.gov/tb/publications/factsheets/testing/xpert_mtb-rif.htm)
4. World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization; 2017. pp. 180–2.
5. Federal Ministry of Health. Department of Public Health: National TB and Leprosy Annual Report. Federal Ministry of Health. 2016
6. World Health Organization. “Tuberculosis”. March 2020. Accessed [online] 03/10/2020 available at <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>
7. World Health Organization. Global tuberculosis report 2017. Washington, DC: WHO Global TB Programme; 2017.
8. Hillemann D, Rüscher-Gerdes S, Boehme C, Richter E. Rapid molecular detection of extrapulmonary Tuberculosis by the automated GeneXpert MTB/RIF system. *J Clin Microbiol*. 2011; 49(4):1202–1205.
9. World Health Organization, Rapid Implementation of the Xpert MTB/RIF Diagnostic Test, World Health Organization. 2011. Available at: [http://whqlibdoc.who.int/publications/2011/9789241501569\\_eng.pdf](http://whqlibdoc.who.int/publications/2011/9789241501569_eng.pdf).
10. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. *J Clin Microbiol*. 2010;48:229–237.
11. World Health Organisation, “Tuberculosis control” World Health Organisation [online] accessed December 24, 2019, available at [https://www.who.int/trade/distance\\_learning/gpgh/gpgh3/en/index7.html](https://www.who.int/trade/distance_learning/gpgh/gpgh3/en/index7.html)
12. Eurosurveillance Editorial Team. WHO publishes Global tuberculosis report 2013? *Eurosurveillance*. 2013 Oct 24;18 (43):20615.
13. Mauch V, Bonsu F, Gyapong M, et al. Free tuberculosis diagnosis and treatment are not enough:

patient cost evidence from three continents. *Int J Tuberc Lung Dis* 2013; 17: 381–387

14. KNCV Tuberculosis Foundation, WHO, the Japan Anti-Tuberculosis Association. The Tool to

Estimate Patients' Costs. Tuberculosis Coalition for Technical Assistance, US Agency for

International Development, 2009.

15. Van Rie A, Page-Shipp L, Scott L, Sanne I, Steven W. Xpert MTB/RIF for point-of-care diagnosis of

TB in high-HIV burden, resource-limited countries: hype or hope? *Expert Rev Mol Diagn* 2010; 10:

937–946.

16. Williamson D A, Basu I, Bower J, Freeman J I, Henderson G, Robert S A. An evaluation of the Xpert

MTB/RIF assay and detection of false-positive rifampicin resistance in *Mycobacterium tuberculosis*.

*Diagn Microbiol Infect Dis* 2012; 74: 207–209.

17. Van Rie A, Mellet K, John M A, et al. False-positive rifampicin resistance on Xpert MTB/RIF: case

report and clinical implications. *Int J Tuberc Lung Dis* 2012; 16: 206–208.

18. Cepheid. Xpert MTB/RIF. Two-hour detection of MTB and resistance to rifampicin. Sunnyvale, CA,

USA: Cepheid, 2009.

19. Cepheid Xpert Dx System. Operator Manual. Software version 4.0. 300– 7607, Rev. C.17.

Sunnyvale, CA, USA: Cepheid, 2010.

20. Unsuccessful Xpert® MTB/RIF results: the Nigerian experience M. Gidado,1 N. Nwokoye,1 P.

Nwadike,1 P. Ajiboye,1 R. Eneogu,1 S. Useni,1 J. Onazi,1 A. Lawanson,2 E. Elom,2 A. Tubi,2 J. Kuye.

21. Cepheid (2009). Cepheid brochure: Xpert®Mtb/RIF. Two-hour detection of MTB and resistance to

rifampicin. Available: [Http://www.cephheid.com](http://www.cephheid.com)

22. Non-conforming rifampicin susceptibility test reports from Xpert MTB/RIF assay; Nkiru N.

Nwokoyeet. al.Non-Conforming Rifampicin Susceptibility Test Reports from Xpert MTB/RIF Assay:

The National Reference Laboratory Experience in Nigeria, *Open Science Journal of Clinical*

*Medicine*. Vol. 2, No. 2, 2014, pp. 59-62

23. Deming WE: Out of the crisis. 1986, Cambridge, Massachusetts: Massachusetts Institute of

Technology

24. Deming WE: The New Economics. 1994, Cambridge, Massachusetts: Massachusetts Institute of Technology
25. Chesher D, Burnett L: Using Shewhart p control charts of external quality-assurance program data to monitor the analytical performance of a clinical chemistry laboratory. *Clinical Chemistry*. 1996, 42: 1478-82.
26. Benneyan JC: Statistical quality control methods in infection control and hospital epidemiology. Part 1: introduction and basic theory. *Infection Control and Hospital Epidemiology*. 1998, 19: 194-214
27. Benneyan JC: Statistical quality control methods in infection control and hospital. Part 2: chart use, statistical properties, and research issues. *Infection Control and Hospital Epidemiology*. 1998, 19: 265-277.
28. Mohammed MA, Cheng KK, Rouse A, Marshall T: Bristol Shipman: and clinical governance: Shewhart's forgotten lessons. *Lancet*. 2001, 357: 463-467. [10.1016/S0140-6736\(00\)04019-8](https://doi.org/10.1016/S0140-6736(00)04019-8)
29. Adab P, Rouse AM, Mohammed MA, Marshall T: Performance league tables: the NHS deserves better. *British Medical Journal*. 2002, 324: 95-5.
30. Spiegelhalter D: Funnel plots for institutional comparison. *Qual Saf Health Care*. 2002, 11: 390-a-391. [10.1136/qhc.11.4.390-a](https://doi.org/10.1136/qhc.11.4.390-a)
31. Analysis of inadequate cervical smears using Shewhart control charts; Wayne N Harrison Mohammed A Mohammed, Michael K Wall & Tom P Marshall *BMC Public Health* volume 4, Article number: 25 (2004)
32. Mustapha, G, Jumoke, O. et.al. Assessment of Gene-Xpert MTB RIF Program Implementation and the Challenges for Enhanced Tuberculosis Diagnosis in Nigeria. *SAARC Journal of Tuberculosis, Lung Diseases and HIV/AIDS*, 12(2), 1-7. <https://doi.org/10.3126/saarctb.v12i2.15948>
33. Berwick DM. Controlling variation in health care: a consultation from Walter Shewhart, *Med Care*, 1991, vol. 29 (pg. 1212-25) [Google ScholarCrossrefPubMed](https://pubmed.ncbi.nlm.nih.gov/121225/)
34. Morton AP, Whitby M, McLaws M-L, Dobson A, McElwain S, Looke D, et al. The application of statistical process control charts to the detection and monitoring of hospital-acquired infections, *J Qual Clin Pract*, 2001, vol. 21 (pg. 112-7) [Google ScholarCrossrefPubMed](https://pubmed.ncbi.nlm.nih.gov/112070/)

35. Ryan TP., Statistical methods for quality improvement, 20002nd edNew YorkJohn Wiley and Sons
36. Hayati F, Maghsoodloo S, Devivo MJ, Carnahan BJ. Control chart for monitoring occupational asthma, J Saf Res, 2006, vol. 37 (pg. 17-26)
37. Boggs PB, Wheeler D, Washburne WF, Hayati F. Peak expiratory flow rate control chart in asthma care: chart construction and use in asthma care, Ann Allergy Asthma Immunol, 1998, vol. 81 (pg. 552-62)
38. Piccoli A, Rizzoni G, Tessarin C, Calconi G, Filippini M, Dugo M, et al. Long-term monitoring of renal transplant patients by a CUSUM test on serum creatinine, Nephron, 1987, vol. 47 (pg. 87-94)
39. Ruth Tennant, Mohammed A. Mohammed, Jamie J. Coleman, Una Martin, Monitoring patients using control charts: a systematic review, International Journal for Quality in Health Care, Volume 19, Issue 4, August 2007, Pages 187–194